Author + information
- Wen Gaiyan and
- Hong Yuan
To investigate the distribution of SLCO1B1 521T>C and 388A>G polymorphisms in Chinese hyperlipidemia patients and explore the impact of these two polymorphisms on the lipid-lowering effects of pitavastatin.
140 Chinese essential hyperlipidemia patients were screened and genotyped for SLCO1B1 521T>C and 388A>G polymorphisms using a tetra-primer amplification refractory mutation system-polymerase chain reaction(ARMS-PCR) and polymerase chain reactio-restrictive fragment length polymorphism (PCR-RFLP). 85 patients were drawn randomly and sequentially received 2mg/d amlodipine for 56 days. The Serum total cholesterol (TC), triglyeride (TG), high-density lipoproteins(HDL) and low-density lipoprotein (LDL) levels were determined at baseline, 28 days and 56 days.
Among these 140 patients, there were 111 (79.3%) patients with 521TT, 27 (19.3%) with 521TC and 2(1.4%) with 521CC. And there were 12(8.6%) patients with 388AA, 57 (40.7%) with 388AG and 71(50.7%) with 388GG. The TC, TG and LDL levels were significantly decreased after 56 days treatment, with effective rate 83.5%. There were no significant difference in the TC, TG, HDL and LDL changes among patients with different SLCO1B1 521T>C or 388A>G genotypes(P > 0.05).
SLCO1B1 388A>G and 521T>C do not affect the lipid-lowering efficacy of pitavastatin.